Header Logo

Connection

JIUN-KAE JACK LEE to Dose-Response Relationship, Drug

Back to Details
This is a "connection" page, showing publications JIUN-KAE JACK LEE has written about Dose-Response Relationship, Drug.
JIUN-KAE JACK LEE
Connection Strength
0.871
Dose-Response Relationship, Drug
  1. Applying Emax model and bivariate thin plate splines to assess drug interactions. Front Biosci (Elite Ed). 2010 01 01; 2(1):279-92.
    View in: PubMed
    Score: 0.193
  2. A semiparametric response surface model for assessing drug interaction. Biometrics. 2008 Jun; 64(2):396-405.
    View in: PubMed
    Score: 0.165
  3. Interaction index and different methods for determining drug interaction in combination therapy. J Biopharm Stat. 2007; 17(3):461-80.
    View in: PubMed
    Score: 0.157
  4. RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. J Natl Cancer Inst. 2013 Jun 05; 105(11):833.
    View in: PubMed
    Score: 0.061
  5. Emax model and interaction index for assessing drug interaction in combination studies. Front Biosci (Elite Ed). 2010 01 01; 2(2):582-601.
    View in: PubMed
    Score: 0.048
  6. A generalized response surface model with varying relative potency for assessing drug interaction. Biometrics. 2006 Dec; 62(4):986-95.
    View in: PubMed
    Score: 0.039
  7. Estimation of k for the poly-k test with application to animal carcinogenicity studies. Stat Med. 2003 Aug 30; 22(16):2619-36.
    View in: PubMed
    Score: 0.031
  8. drexplorer: A tool to explore dose-response relationships and drug-drug interactions. Bioinformatics. 2015 May 15; 31(10):1692-4.
    View in: PubMed
    Score: 0.017
  9. Antitumor activity of AZ64 via G2/M arrest in non-small cell lung cancer. Int J Oncol. 2012 Nov; 41(5):1798-808.
    View in: PubMed
    Score: 0.015
  10. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One. 2012; 7(4):e34833.
    View in: PubMed
    Score: 0.014
  11. Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention. Cancer Prev Res (Phila). 2010 Aug; 3(8):917-28.
    View in: PubMed
    Score: 0.013
  12. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res. 2010 Feb 15; 16(4):1289-97.
    View in: PubMed
    Score: 0.012
  13. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila). 2010 Feb; 3(2):148-59.
    View in: PubMed
    Score: 0.012
  14. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009 Nov; 2(11):931-41.
    View in: PubMed
    Score: 0.012
  15. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009 May 20; 101(10):708-20.
    View in: PubMed
    Score: 0.012
  16. High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila). 2009 Jan; 2(1):22-6.
    View in: PubMed
    Score: 0.011
  17. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):2178-84.
    View in: PubMed
    Score: 0.009
  18. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005 Apr 10; 23(11):2544-55.
    View in: PubMed
    Score: 0.009
  19. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. Clin Cancer Res. 2003 Jul; 9(7):2400-5.
    View in: PubMed
    Score: 0.008
  20. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog. J Clin Oncol. 2001 Mar 01; 19(5):1493-500.
    View in: PubMed
    Score: 0.007
  21. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. Cancer. 1999 Dec 01; 86(11):2291-300.
    View in: PubMed
    Score: 0.006
  22. Accrual strategies for phase I trials with delayed patient outcome. Stat Med. 1999 May 30; 18(10):1155-69.
    View in: PubMed
    Score: 0.006
  23. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998 Apr; 16(4):1325-30.
    View in: PubMed
    Score: 0.005
  24. Phase I dose de-escalation trial of alpha-difluoromethylornithine in patients with grade 3 cervical intraepithelial neoplasia. Clin Cancer Res. 1998 Feb; 4(2):303-10.
    View in: PubMed
    Score: 0.005
  25. Anticlastogenic effects of 13-cis-retinoic acid in vitro. Eur J Cancer. 1992; 29A(1):137-40.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.